Teva Contemplates Selling $2 Billion Active Ingredients Division

Teva Pharmaceuticals considers selling its $2 billion active pharmaceutical ingredients (API) unit as part of its "Pivot to Growth" strategy.

The company is reviewing options and gauging interest, with a decision yet to be made, reported Bloomberg on Jul. 5.

Teva's API unit produces over 400 APIs across 16 plants, serving 1,000+ customers and employing around 5,000 people. Teva spokesperson neither confirms nor denies the potential sale but highlights the unit's growth potential, said Bloomberg.

The move follows CEO Richard Francis' strategy focusing on commercial portfolio, biosimilars, generics, and targeted capital allocation. Teva aims to shift focus to high-value opportunities rather than its generics business. In 2022, Teva reported $14.9 billion in revenues, with generics sales declining to $8.6 billion across its three global regions ($9 billion in 2021). Q1 2023 sales for the company reached $3.7 billion, which is flat compared to last year.

Teva Pharmaceuticals is considering selling its API unit. © Teva...
Teva Pharmaceuticals is considering selling its API unit. © Teva Pharmaceuticals

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.